Seagen Inc. – NASDAQ:SGEN
Founder-led company
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 6 hours
Seagen stock price monthly change
+7.29%
month
Seagen stock price quarterly change
+11.07%
quarter
Seagen stock price yearly change
+70.63%
year
Seagen key metrics
Market Cap | 43.15B |
Enterprise value | 37.57B |
P/E | -61.93 |
EV/Sales | 19.14 |
EV/EBITDA | -70.56 |
Price/Sales | 19.28 |
Price/Book | 13.50 |
PEG ratio | -5.72 |
EPS | -4.01 |
Revenue | 2.30B |
EBITDA | -819.22M |
Income | -750.22M |
Revenue Q/Q | 27.11% |
Revenue Y/Y | 23.40% |
Profit margin | -31.1% |
Oper. margin | -31.24% |
Gross margin | 79.1% |
EBIT margin | -31.24% |
EBITDA margin | -35.61% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSeagen stock price history
Seagen stock forecast
Seagen financial statements
| Dec 2022 | 528.15M | -148.17M | -28.05% |
|---|---|---|---|
| Mar 2023 | 519.71M | -174.73M | -33.62% |
| Jun 2023 | 603.83M | -211.52M | -35.03% |
| Sep 2023 | 648.65M | -215.78M | -33.27% |
| 2025 | 4.17B | 156.66M | 3.76% |
|---|
Analysts Price target
Financials & Ratios estimates
| Dec 2022 | 3674532000 | 870.71M | 23.7% |
|---|---|---|---|
| Mar 2023 | 3543296000 | 820.14M | 23.15% |
| Jun 2023 | 3495382000 | 876.32M | 25.07% |
| Sep 2023 | 3634261000 | 1.08B | 29.82% |
| Dec 2022 | -79.44M | -36.49M | 65.34M |
|---|---|---|---|
| Mar 2023 | -249.64M | 232.33M | 29.93M |
| Jun 2023 | -175.24M | 133.08M | 13.81M |
| Sep 2023 | -35.82M | 142.49M | 15.52M |
Seagen alternative data
| Aug 2023 | 3,256 |
|---|---|
| Sep 2023 | 3,256 |
| Oct 2023 | 3,256 |
| Nov 2023 | 3,256 |
| Dec 2023 | 3,256 |
| Jan 2024 | 3,256 |
| Feb 2024 | 3,256 |
| Mar 2024 | 3,256 |
| Apr 2024 | 3,256 |
| May 2024 | 3,256 |
| Jun 2024 | 3,256 |
| Jul 2024 | 3,256 |
Seagen other data
23.26%
-66.65%
of SGEN is owned by hedge funds
382
-137
42.94M
-123.18M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2022 | 0 | 10532 |
| Jan 2023 | 0 | 30578 |
| Feb 2023 | 0 | 75729 |
| Mar 2023 | 0 | 50484 |
| Apr 2023 | 0 | 102470 |
| May 2023 | 0 | 27357 |
| Jun 2023 | 0 | 16215 |
| Jul 2023 | 0 | 708 |
| Aug 2023 | 0 | 18034 |
| Sep 2023 | 0 | 9125 |
| Nov 2023 | 0 | 19405 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | EPSTEIN DAVID R director, officer: CEO | Common Stock | 10,620 | $213.01 | $2,262,166 | ||
Sale | HIMES VAUGHN B officer: Chief Technical Officer | Common Stock | 8,567 | $213.31 | $1,827,427 | ||
Sale | HIMES VAUGHN B officer: Chief Technical Officer | Common Stock | 218 | $213.88 | $46,626 | ||
Sale | DANSEY ROGER D officer: Presiden.. | Common Stock | 71 | $206.5 | $14,662 | ||
Sale | HIMES VAUGHN B officer: Chief Technical Officer | Common Stock | 80 | $206.5 | $16,520 | ||
Sale | ROMP CHARLES R officer: EVP, Com.. | Common Stock | 45 | $206.5 | $9,293 | ||
Sale | SIMPSON TODD E officer: Chief Fi.. | Common Stock | 80 | $206.5 | $16,520 | ||
Sale | LIU JEAN I officer: Chief Le.. | Common Stock | 64 | $206.5 | $13,216 | ||
Option | HIMES VAUGHN B officer: Chief Technical Officer | Common Stock | 8,785 | $44.09 | $387,331 | ||
Sale | HIMES VAUGHN B officer: Chief Technical Officer | Common Stock | 8,785 | $205.76 | $1,807,602 |
| Patent |
|---|
Application Filling date: 2 May 2022 Issue date: 25 Aug 2022 |
Application Filling date: 1 Dec 2021 Issue date: 18 Aug 2022 |
Application Filling date: 25 Apr 2022 Issue date: 11 Aug 2022 |
Grant Utility: Anti-TIGIT antibodies Filling date: 22 Aug 2019 Issue date: 2 Aug 2022 |
Application Filling date: 4 Jun 2020 Issue date: 28 Jul 2022 |
Application Filling date: 22 Nov 2021 Issue date: 21 Jul 2022 |
Application Filling date: 1 Nov 2018 Issue date: 21 Jul 2022 |
Grant Filling date: 7 Sep 2018 Issue date: 19 Jul 2022 |
Grant Filling date: 25 Jun 2021 Issue date: 28 Jun 2022 |
Application Filling date: 27 Oct 2021 Issue date: 23 Jun 2022 |
| Quarter | Transcript |
|---|---|
| Q4 2022 15 Feb 2023 | Q4 2022 Earnings Call Transcript |
| Q3 2022 27 Oct 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 28 Jul 2022 | Q2 2022 Earnings Call Transcript |
| Q1 2022 28 Apr 2022 | Q1 2022 Earnings Call Transcript |
5 Biotech Acquisition Targets To Accumulate In 2024
8 Tax-Loss Sell Alerts For December
Pfizer: Value Investment Opportunity After Recent Price Decline
Pfizer Stock: Interesting, If Discipline Returns
Incyte: One Of The Most Undervalued Pharmaceuticals
Pfizer Vs. Gilead Sciences: COVID-19 Battle Of Pharma Titans
Genmab Is Down To Attractive Levels
Pfizer: Not Quite Dead Money Walking
Pfizer: Ridiculous Selloff To A 2-Year Low
-
When is Seagen's next earnings date?
Unfortunately, Seagen's (SGEN) next earnings date is currently unknown.
-
Does Seagen pay dividends?
No, Seagen does not pay dividends.
-
How much money does Seagen make?
Seagen has a market capitalization of 43.15B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 24.65% to 1.96B US dollars.
-
What is Seagen's stock symbol?
Seagen Inc. is traded on the NASDAQ under the ticker symbol "SGEN".
-
What is Seagen's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Seagen?
Shares of Seagen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Seagen's key executives?
Seagen's management team includes the following people:
- Dr. Clay B. Siegall Co-Founder, Chairman, Pres & Chief Executive Officer(age: 64, pay: $2,640,000)
- Dr. Roger D. Dansey M.D. Chief Medical Officer(age: 68, pay: $1,650,000)
- Ms. Jean I. Liu J.D., M.S. Chief Legal Officer(age: 57, pay: $963,450)
- Mr. Charles R. Romp Executive Vice President of Commercial U.S.(age: 57, pay: $829,160)
- Mr. Todd E. Simpson Chief Financial Officer(age: 64, pay: $620,670)
-
Is Seagen founder-led company?
Yes, Seagen is a company led by its founder Dr. Clay B. Siegall.
-
How many employees does Seagen have?
As Jul 2024, Seagen employs 3,256 workers.
-
When Seagen went public?
Seagen Inc. is publicly traded company for more then 24 years since IPO on 9 Mar 2001.
-
What is Seagen's official website?
The official website for Seagen is seagen.com.
-
Where are Seagen's headquarters?
Seagen is headquartered at 21823 30th Drive SE, Bothell, WA.
-
How can i contact Seagen?
Seagen's mailing address is 21823 30th Drive SE, Bothell, WA and company can be reached via phone at 425 527 4000.
Seagen company profile:
Seagen Inc.
seagen.comExchange:
NASDAQ
Full time employees:
3,256
Industry:
Biotechnology
Sector:
Healthcare
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
21823 30th Drive SE
Bothell, WA 98021
Bothell, WA 98021
CIK: 0001060736
ISIN: US81181C1045
CUSIP: 81181C104
